Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Rating of “Buy” by Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received a consensus rating of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $17.80.

A number of equities research analysts have recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Cantor Fitzgerald cut their target price on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 25th. Needham & Company LLC cut their target price on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. Finally, HC Wainwright raised shares of Artiva Biotherapeutics to a “buy” rating and set a $12.00 price target for the company in a research report on Wednesday, June 11th.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN grew its holdings in shares of Artiva Biotherapeutics by 64.0% in the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after purchasing an additional 3,361 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Artiva Biotherapeutics by 262.1% in the fourth quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock worth $100,000 after purchasing an additional 7,151 shares during the last quarter. Nuveen LLC bought a new position in shares of Artiva Biotherapeutics in the first quarter worth about $144,000. Charles Schwab Investment Management Inc. grew its holdings in Artiva Biotherapeutics by 26.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock worth $165,000 after acquiring an additional 11,355 shares in the last quarter. Finally, Deutsche Bank AG bought a new position in Artiva Biotherapeutics during the 4th quarter worth about $216,000.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $2.59 on Friday. The firm’s fifty day moving average price is $1.89 and its 200-day moving average price is $3.71. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Thursday, May 8th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.15). On average, equities analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.